Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
A prospective multicenter registry in real-world Japanese patients undergoing DAPT for three
months after stenting. To assess the long-term safety of Endeavor Zotarolimus-eluting stent
through noninferiority in the primary endpoint between two different continuous regimen
(three and twelve months) groups of DAPT after stenting with Endeavor Zotarolimus-eluting
stent in real-world Japanese patients and to examine the optimal duration of DAPT after
stenting with Endeavor Zotarolimus-eluting stent. The long-term DAPT group in the present
clinical study (to be appropriated from the post-marketing surveillance of Endeavor) should
consist of consecutive patients undergoing DAPT for twelve months after stenting, while the
short-term DAPT group (to be newly registered in the present clinical study) should consist
of patients who are instructed to undergo DAPT for three months after stenting.
Phase:
Phase 4
Details
Lead Sponsor:
Associations for Establishment of Evidence in Interventions